rs1013724730

Variant summary

Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_ModerateBS2

The NM_004364.5(CEBPA):ā€‹c.364G>Cā€‹(p.Gly122Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000898 in 1,202,562 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā˜…ā˜…).

Frequency

Genomes: š‘“ 0.00029 ( 0 hom., cov: 32)
Exomes š‘“: 0.000063 ( 0 hom. )

Consequence

CEBPA
NM_004364.5 missense

Scores

2
1
16

Clinical Significance

Uncertain significance criteria provided, multiple submitters, no conflicts U:8

Conservation

PhyloP100: 2.53
Variant links:
Genes affected
CEBPA (HGNC:1833): (CCAAT enhancer binding protein alpha) This intronless gene encodes a transcription factor that contains a basic leucine zipper (bZIP) domain and recognizes the CCAAT motif in the promoters of target genes. The encoded protein functions in homodimers and also heterodimers with CCAAT/enhancer-binding proteins beta and gamma. Activity of this protein can modulate the expression of genes involved in cell cycle regulation as well as in body weight homeostasis. Mutation of this gene is associated with acute myeloid leukemia. The use of alternative in-frame non-AUG (GUG) and AUG start codons results in protein isoforms with different lengths. Differential translation initiation is mediated by an out-of-frame, upstream open reading frame which is located between the GUG and the first AUG start codons. [provided by RefSeq, Dec 2013]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_benign. Variant got -6 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.12777963).
BS2
High AC in GnomAd4 at 42 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
CEBPANM_004364.5 linkuse as main transcriptc.364G>C p.Gly122Arg missense_variant 1/1 ENST00000498907.3 NP_004355.2
CEBPANM_001287424.2 linkuse as main transcriptc.469G>C p.Gly157Arg missense_variant 1/1 NP_001274353.1
CEBPANM_001287435.2 linkuse as main transcriptc.322G>C p.Gly108Arg missense_variant 1/1 NP_001274364.1
CEBPANM_001285829.2 linkuse as main transcriptc.7G>C p.Gly3Arg missense_variant 1/1 NP_001272758.1

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
CEBPAENST00000498907.3 linkuse as main transcriptc.364G>C p.Gly122Arg missense_variant 1/1 NM_004364.5 ENSP00000427514 P1P49715-1

Frequencies

GnomAD3 genomes
AF:
0.000285
AC:
42
AN:
147210
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000837
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000134
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000752
Gnomad OTH
AF:
0.000490
GnomAD4 exome
AF:
0.0000625
AC:
66
AN:
1055222
Hom.:
0
Cov.:
33
AF XY:
0.0000600
AC XY:
30
AN XY:
500000
show subpopulations
Gnomad4 AFR exome
AF:
0.000944
Gnomad4 AMR exome
AF:
0.000431
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000478
Gnomad4 OTH exome
AF:
0.00
GnomAD4 genome
AF:
0.000285
AC:
42
AN:
147340
Hom.:
0
Cov.:
32
AF XY:
0.000320
AC XY:
23
AN XY:
71920
show subpopulations
Gnomad4 AFR
AF:
0.000834
Gnomad4 AMR
AF:
0.000134
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000752
Gnomad4 OTH
AF:
0.000485
Alfa
AF:
0.000498
Hom.:
0
Bravo
AF:
0.000227

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Acute myeloid leukemia Uncertain:4
Uncertain significance, criteria provided, single submitterclinical testingBaylor GeneticsMay 19, 2023- -
Uncertain significance, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpDec 01, 2023This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 122 of the CEBPA protein (p.Gly122Arg). This variant is present in population databases (no rsID available, gnomAD 0.09%), and has an allele count higher than expected for a pathogenic variant. This variant has not been reported in the literature in individuals affected with CEBPA-related conditions. ClinVar contains an entry for this variant (Variation ID: 526801). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CEBPA protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Uncertain significance, criteria provided, single submitterclinical testingRevvity Omics, RevvityNov 26, 2019- -
Uncertain significance, criteria provided, single submitterclinical testingFulgent Genetics, Fulgent GeneticsApr 15, 2022- -
not specified Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingGenetic Services Laboratory, University of ChicagoAug 17, 2020DNA sequence analysis of the CEBPA gene demonstrated a sequence change, c.364G>C, in exon 1 that results in an amino acid change, p.Gly122Arg. This sequence change does not appear to have been previously described in patients with CEBPA-related disorders and has been described in the gnomAD database with a frequency of 0.086% in the African sub-population (dbSNP rs1013724730). The p.Gly122Arg change affects a poorly conserved amino acid residue located in a domain of the CEBPA protein that is known to be functional. The p.Gly122Arg substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Due to these contrasting evidences and the lack of functional studies, the clinical significance of the p.Gly122Arg change remains unknown at this time. -
not provided Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingGeneDxJul 08, 2022In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge -
CEBPA-related disorder Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingPreventionGenetics, part of Exact SciencesSep 13, 2022The CEBPA c.364G>C variant is predicted to result in the amino acid substitution p.Gly122Arg. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.086% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/19-33792957-C-G), and it is documented as a variant of uncertain significance by multiple labs in the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/variation/526801/evidence/). Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
Hereditary cancer-predisposing syndrome Uncertain:1
Uncertain significance, criteria provided, single submittercurationSema4, Sema4May 30, 2021- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
0.35
BayesDel_addAF
Benign
-0.53
T
BayesDel_noAF
Benign
-0.60
CADD
Benign
23
DANN
Benign
0.91
DEOGEN2
Benign
0.16
T
Eigen
Benign
-0.79
Eigen_PC
Benign
-0.63
FATHMM_MKL
Benign
0.30
N
LIST_S2
Benign
0.60
T
M_CAP
Pathogenic
0.67
D
MetaRNN
Benign
0.13
T
MetaSVM
Benign
-1.0
T
MutationAssessor
Benign
0.0
N
MutationTaster
Benign
1.0
N
PrimateAI
Pathogenic
0.92
D
PROVEAN
Benign
-0.21
N
REVEL
Benign
0.029
Sift
Benign
0.35
T
Sift4G
Benign
0.20
T
Polyphen
0.012
B
Vest4
0.22
MutPred
0.30
Gain of solvent accessibility (P = 0.0037);
MVP
0.26
ClinPred
0.13
T
GERP RS
3.6
Varity_R
0.094
gMVP
0.17

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs1013724730; hg19: chr19-33792957; API